Tatiana Prowell, Associate Professor of Oncology at Johns Hopkins School of Medicine and Breast Cancer Scientific Liaison at the U.S. Food and Drug Administration, shared a post on X:
“Randomized trial in 234 ppl with early breast cancer on capecitabine for postneoadjuvant residual disease found methylcobalamin (Vit B12) 0.5 mg 3x per day was safe and cut risk of grade 2+ hand-foot syndrome in half vs placebo. NNT ~7.
This is an important supportive care study. Hand-foot syndrome is a common side effect of capecitabine that impairs quality of life and may result in discontinuation of chemo.
Giving oral vit B12 as above is simple and low cost.”
Title: Effect of methylcobalamin on capecitabine induced hand-foot syndrome in patients with HER2 negative early breast cancer: multicentre, double blind, randomised, placebo controlled, phase 3 trial
Authors: Yuan Xia, Yingying Zhu, Li Ling, Fei Xu, Yaping Yang, Jinhui Ye, Weige Tan, Zouxiang Chen, Qiang Liu, Wei Wei, Jun Zhang, Ailing Zhang, Lehong Zhang, Erwei Song, Chang Gong
Read The Full Article at The BMJ.
More posts featuring Tatiana Prowell on OncoDaily.
